Short answer
XOMA Royalty Corp (XOMA) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 1.01 (Entry into a Material Definitive Agreement), Item 3.01 (Notice of Delisting), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 8.01 (Other Events). Holding-company reorganization preserved shareholders’ one-for-one common-stock ownership and converted equity awards on equivalent terms.
- This filing includes Item 3.01, an item that often signal trouble.
XOMA Royalty Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Holding-company reorganization preserved shareholders’ one-for-one common-stock ownership and converted equity awards on equivalent terms
- Company converted to Delaware LLC, separating operating assets and liabilities between HoldCo and XOMA Royalty LLC
- HoldCo transferred 75% of XOMA Royalty LLC to XOMA CVR Trust for contingent value rights holders
- CVRs issued pro rata to common and preferred shareholders, based on preferred shares converted to common
- CVR payments depend on future distributions from the trust’s XOMA Royalty LLC interest, creating contingent rather than immediate consideration
Item 1.02 · Termination of a Material Definitive Agreement
- XRL 1 LLC terminated its December 15, 2023 Loan Agreement in connection with the merger
- Parent fully discharged all outstanding borrowing obligations on behalf of XOMA
- Debt repayment removes the Loan Agreement and associated lender commitments from XOMA’s capital structure
- Blue Owl Capital Corporation served as administrative agent for the lenders
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Common shareholders received $39.00 cash per share, subject to withholding taxes
- Shareholders also received CVRs tied to contingent payments from XOMA Royalty LLC
- Series A and Series B preferred stock redeemed July 14, 2026, including accrued unpaid dividends
- Merger completion converts XOMA into a cash-and-contingent-value realization for equity holders
Item 3.01 · Notice of Delisting
- Merger consummated, triggering Nasdaq delisting of XOMA common shares
- Trading halt and delisting requested before market open July 14, 2026
- Form 25 filing will remove Shares from Nasdaq and deregister them under Exchange Act Section 12(b)
- Planned Form 15 filing would terminate registration and suspend SEC reporting obligations
Item 3.03 · Material Modification to Rights of Security Holders
- Control-change information incorporated from the filing’s Introductory Note and Items 2.01 and 5.02
- Potential shareholder-rights implications depend on the acquisition and leadership-change details in those referenced sections
Item 5.01 · Changes in Control of Registrant
- Item 5.01 disclosure references the Introductory Note, indicating a control-related event described elsewhere in the filing
- Investor focus: identify any new controlling party, ownership shift, or governance changes in the referenced Introductory Note
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders approved the merger agreement, holding-company reorganization, and related compensation proposal
- Merger agreement: 15,924,106 votes for versus 98,100 against
- Holding-company reorganization: 15,924,259 votes for versus 98,089 against
- Compensation proposal: 15,745,257 votes for versus 272,303 against
- Approval clears the shareholder-vote condition for the proposed transaction and corporate restructuring
Item 8.01 · Other Events
- Closing of Parent’s acquisition of XOMA Royalty announced July 14, 2026
- Transaction creates integration, execution and potential litigation risks for shareholders
- Expected acquisition benefits may be delayed or fail to materialize
- Royalty and pipeline value remains dependent on partners, clinical outcomes and regulatory approvals
- Exhibit 99.1 contains the substantive closing announcement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other XOMA Royalty Corp 8-K filings
Get the next XOMA 8-K as it lands
Follow XOMA for push alerts, or ask the research agent what this filing means.